Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - OPIANT PHARMACEUTICALS, INC.v457102_ex99-1.htm

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  January 11, 2017

 

OPIANT PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-55330   46-4744124

(State or other jurisdiction of
incorporation)

 

(Commission File Number

 

  (IRS Employer
Identification No.)

  

401 Wilshire Blvd., 12th Floor

Santa Monica, CA

 

 

90401

(Address of Principal Executive Offices)

  (Zip Cope)

 

 (424) 252-4756

Registrant’s telephone number, including area code

 

 
(Former name or former address if changed since last report,)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

Item 8.01Other Events.

 

On January 11, 2017, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its 2017 corporate and clinical goals which include, but are not limited to: (i) initiating a Phase 2 study in Bulimia Nervosa; (ii) continuing to provide ongoing development and intellectual property support for Adapt Pharma Limited, the Company’s NARCAN® Nasal Spray commercialization partner; (iii) hiring a Chief Scientific Officer; (iv) completing an uplisting to a major stock exchange; and (v) reincorporating from Nevada to Delaware.

 

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit No. Description
   
99.1 Opiant Pharmaceuticals, Inc. Press Release, dated January 11, 2017.

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

    Opiant Pharmaceuticals, Inc.
     
Date: January 18, 2017 By: /s/ Dr. Roger Crystal
    Name: Dr. Roger Crystal
    Title: President and Chief Executive Officer